All In Biotech

Drug Trial Radar · NCT07594847

A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects

A Phase I, Single-center, Randomized, Double-blind, Placebo- and Positive-controlled, Four-period, Crossover Clinical Study to Evaluate the Effect of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Mar 7, 2026

Primary completion

Sep 25, 2026

Study completion Nov 6, 2026

Sponsor

Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this trial is to evaluate the effect of a single oral dose of HDM1002 tablets on the QT/QTc interval in healthy subjects.

Conditions

  • Healthy Adult Subject

Interventions

  • HDM1002 200 mgDrug

    HDM1002 tablet, oral, 200 mg single dose

  • HDM1002 400 mgDrug

    HDM1002 tablet, oral, 400 mg single dose

  • PlaceboDrug

    Placebo tablet, oral, single dose

  • Moxifloxacin 400 mgDrug

    Moxifloxacin tablet, oral, 400 mg single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correlation between HDM1002 Plasma Concentration and ΔΔQTcTime frame: From the base line ECG (Day -1) to end of the period, up to 48 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PKUcare Luzhong Hospital

    Zibo, Shangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.